Lynx1 Capital Management as of March 31, 2026
Portfolio Holdings for Lynx1 Capital Management
Lynx1 Capital Management holds 23 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Stoke Therapeutics (STOK) | 24.5 | $155M | 4.8M | 32.56 | |
| Gh Research Ordinary Shares (GHRS) | 23.9 | $151M | 11M | 14.06 | |
| Cullinan Oncology (CGEM) | 20.1 | $127M | 9.0M | 14.21 | |
| Agios Pharmaceuticals (AGIO) | 14.0 | $88M | 2.6M | 33.83 | |
| Denali Therapeutics (DNLI) | 5.7 | $36M | 1.9M | 19.20 | |
| C4 Therapeutics Com Stk (CCCC) | 2.9 | $18M | 7.0M | 2.63 | |
| Korro Bio (KRRO) | 2.8 | $17M | 1.5M | 11.32 | |
| Tscan Therapeutics (TCRX) | 1.3 | $8.1M | 8.0M | 1.01 | |
| Xencor (XNCR) | 1.0 | $6.5M | 536k | 12.06 | |
| Precision Biosciences Com New (DTIL) | 0.9 | $5.4M | 985k | 5.50 | |
| Passage Bio Com New (PASG) | 0.8 | $4.9M | 624k | 7.85 | |
| Neuphoria Therapeutics (NEUP) | 0.6 | $3.6M | 875k | 4.07 | |
| Entrada Therapeutics (TRDA) | 0.4 | $2.7M | 212k | 12.62 | |
| Cg Oncology (CGON) | 0.3 | $2.1M | 32k | 67.68 | |
| Immatics SHS (IMTX) | 0.3 | $2.1M | 217k | 9.84 | |
| Design Therapeutics (DSGN) | 0.2 | $1.3M | 120k | 10.64 | |
| Vyne Therapeutics (VYNE) | 0.2 | $973k | 1.6M | 0.60 | |
| Werewolf Therapeutics (HOWL) | 0.1 | $548k | 658k | 0.83 | |
| Ibio Com New (IBIO) | 0.0 | $129k | 68k | 1.90 | |
| Bolt Biotherapeutics Com New (BOLT) | 0.0 | $124k | 31k | 4.04 | |
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.0 | $111k | 69k | 1.62 | |
| Absci Corp (ABSI) | 0.0 | $64k | 21k | 3.00 | |
| Traws Pharma Com New (TRAW) | 0.0 | $28k | 15k | 1.83 |
